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Abstract 
Objective: The aim of this review was to analyze the state of the art about HE4 and follow-up in 
patients treated for ovarian cancer. 
Methods: A literature search was conducted in the MEDLINE database using the key words “HE4” 
and “ovarian cancer” and “recurrence” or “relapse” or “follow up.” 
Results: Seven of 28 clinical studies were selected. Four studies were prospective, and all of them 
were based on a small number of patients (8–73 women). A failure of HE4 levels to normalize at 
completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer 
follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian 
cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead 
time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association 
with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the 
surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after 
the recurrence. 
Conclusions: These preliminary data start to suggest a superiority of HE4 over CA-125 in the 
detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians 
to personalize the follow-up program, whereas its predictive role could be useful to plan the 
treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further 
investigated in prospective randomized multicentric studies. 
 
 
Ovarian cancer (OC) is the second most common gynecologic cancer and the leading cause of death 
from gynecologic malignancy among women in industrialized countries.1 The global incidence in 
both developed and developing countries can be estimated as 165,000 new cases per year.2 A heavy 
difference in prognosis exists between the early-stage disease (International Federation of 
Gynecology and Obstetrics [FIGO] I-II) and the advanced stages (FIGO III-IV).3 Unfortunately, at 
present, we do not have an effective screening strategy for this malignancy; most (>80%) of the 
cases are diagnosed as advanced-stage disease, and this explains the high mortality rate.4 
These aggressive features of the OC encouraged in recent years a big effort in order to find new 
strategies for early diagnosis of OC. These studies focused mainly on new markers and diagnostic 
algorithms.5 
Among new markers, HE4 is one of the most promising.6 It is a protein initially identified in the 
epithelium of the distal epididymis and may be involved in sperm maturation; it is also called 
WFDC2 because of its molecular structure, containing 2 whey acid protein domains and a 4-
disulfide-bond core with 8 cysteine residues. Further studies demonstrated the presence of HE4 in 
the female genitourinary tract, the respiratory tract, the renal epithelium, and the salivary ducts, 
whereas it is absent in the gastrointestinal tract, liver, pancreas, spleen, lymph nodes, mammary 
gland, and nervous system. Despite its wide distribution, it is overexpressed only in pathological 
tissue, and it has demonstrated good sensibility and specificity in detecting OC, overcoming the 
traditional role of CA-125.7 
Despite an aggressive upfront treatment strategy (surgery plus chemotherapy), leading to clinical 
remission in more than 80% of patients, the relapse-free survival varies from 95.8% (for early FIGO 
stages) to 33.6% (for advanced stages) at 2 years.6 
At present, periodical evaluation of CA-125 combined with physical examination is the 
recommended strategy for OC follow-up, typically every 3 to 4 months in the first 1 to 2 years after 
primary treatment and then every 6 months until the fifth year.8–10 Five years’ overall survival 
rate, however, is 49.7% (ranging from 83%–89% in stage I OC to 18% in stage IV).11 New 
markers should be tested in the follow-up of patients with OC to improve the surveillance program 
performance: the challenge is to try to anticipate the diagnosis of OC recurrence and to translate this 
early diagnosis of relapse in a survival improvement. 
 
The aim of this review was to examine the state of art about HE4 and follow-up of OC through a 
complete literature search. 
MATERIALS AND METHODS 
 
A literature search was conducted in the MEDLINE database using the key words “HE4” and 
“ovarian cancer” and “recurrence” or “HE4” and “ovarian cancer” and “relapse” or “HE4” and 
“ovarian cancer” and “follow up.” Then, a ClinicalTrials.gov search for “ovarian cancer follow-up 
and HE4” was carried out. 
RESULTS 
Twenty-eight articles were found from 2005 to 2014. Among these articles, 7 clinical studies 
were selected (Table 1),1,3,4,6,12–14 excluding the reviews and the articles showing poor 
consistency with our topic. The ClinicalTrials.gov search revealed a French trial titled 
“Determination of the prognostic and predictive value of the new marker HE4 in metastatic OC 
monitoring”; this trial is still recruiting, and no data have been published yet. 
   
 
The first study to analyze the role of HE4 in OC follow-up was published by Havrilesky et al 4 in 
2008: they analyzed the utility of a combination of multiple markers in differential diagnosis of 
benign and neoplastic pelvic masses at the first diagnosis, and then the application of a subset of 
these markers in the follow-up. Monitoring 27 patients with recurrent OC, they found 100% 
sensitivity for HE4, MMP7, and glycodelin combination, and 96% sensitivity using CA-125 alone. 
At least one of the markers from the panel showed increased levels 6 to 69 weeks before CA-125 
rise and before clinical signs of relapse in 52% of the patients. In 41% of women with recurrent OC, 
CA-125 rose simultaneously to the biomarker panel, and in 4% in advance of it. 
Anastasi et al 6 included 8 patients in a follow-up study based on the availability of serum samples 
at diagnosis of OC and every 4 months after surgery; among them, 20 months after debulking 
surgery, 5 women showed a rise in the levels of the tumor markers (HE4 and CA-125). In these 
patients, the rise of HE4 always preceded the rise of CA-125 by 5 to 8 months and coincided with 
the recurrence of the disease, as confirmed by instrumental examination or by the death of 3 
patients. 
In 2012, Schummer et al 12 compared the effectiveness of CA-125, HE4, mesothelin, and MMP7 in 
OC follow-up. The study involved 23 patients: 20 women developed a relapse of OC with a median 
progression-free-interval of 18 months (range, 9–48 months). Among them, 3 showed a rise of CA-
125 alone, 1 was detected first by CA-125, 5 were revealed only by HE4, 2 were detected first by 
HE4 and then by CA-125 rise, 6 were simultaneously diagnosed by HE4 and CA-125; in 3 cases of 
recurrence, there was no markers’ elevation. HE4 displayed advantages over CA-125 in predicting 
recurrence, confirming a better lead time than for CA-125 and proving to be useful in cases without 
CA-125 elevation too. Authors suggest that HE4 may be more sensitive than imaging in confirming 
elevated CA-125 levels, with several advantages such as being a cheaper examination and lacking 
of ionizing radiations. HE4 could be used alongside CA-125 to identify patients with persistent 
disease not detected by physical examination or computed tomography (CT) imaging after primary 
treatment, in order to identify a high-risk group who could potentially benefit from additional 
treatment or more intensive monitoring. 
Granato et al 1 investigated in 2012 the role of CA-125, HE4, and CA-72.4 at the diagnosis of OC 
in 39 patients and throughout the follow-up in 20 of them (6–48 months of follow-up). A 
statistically significant difference was observed between the elevation of HE4 and CA72.4 over that 
observed for CA-125 at the diagnosis of disease recurrence. Authors concluded that the 
combination of HE4 and CA-72.4 performs better than CA-125 alone and better than other markers’ 
combination and reveals a positivity in more than 75% of the patients at OC relapse. 
Plotti et al 3 published the first prospective controlled study in the literature evaluating the 
sensitivity and specificity of HE4 and CA-125 in detecting recurrent OC. They recruited 34 patients 
with suspicious recurrent OC and 34 women with benign adnexal pathology. CA-125 (normal value 
is considered <35 U/mL) sensitivity and specificity in detecting recurrent OC were 35% and 59%, 
respectively. HE4 sensitivity and specificity (with cutoff 70 pmol/L) were 73% and 100%, 
respectively. 
Combining CA-125 and HE4 at cutoff of 70 pmol/L, the sensitivity to detect recurrent OC is 76% 
with a specificity of 100%. The authors conclude that the combination of CA-125 and HE4 at cutoff 
of 70 pmol/L improves the overall sensitivity and specificity of CA-125 alone, suggesting a useful 
application of HE4 in strategies for surveillance of OC recurrence. They also underline the 
importance of further studies to determine the correlation between HE4 and the amount of recurrent 
disease volume. 
Manganaro 13 retrospectively enrolled 21 patients with FIGO stage III/IV epithelial OC who 
underwent surgery and adjuvant chemotherapy. From each patient, 3 serum samples were collected 
at time interval I (1–3 months from surgery), II (4–6 months from surgery), III (7–10 months from 
surgery). On these samples, HE4 and CA-125 were determined by enzyme immunoassay and 
immunoradiometric assay. At the same time, contrast-enhanced CT was also performed at 6-month 
intervals. During the follow-up study, 9 patients had recurrent disease, and 12 had stable disease. In 
patients with relapsed OC, increased values of HE4 were observed in 22%, 78%, and 89% of the 
samples, respectively, within the time intervals I, II, III. Positivity for CA-125 was revealed later (at 
time interval III) and only in 44% of patients. In contrast, for patients with stable disease, only CA-
125 showed high values. These data lead authors to conclude that HE4 could be useful as an early 
biomarker for recurrence of OC. Moreover, data provided by contrast-enhanced CT showed 
significant correlation with biochemical results, suggesting the usefulness of their combined 
employment. 
 
Braicu et al 14 prospectively enrolled 73 patients with OC first recurrence: they showed that HE4 is 
an independent predictive factor for maximal tumor reduction in terms of macroscopic tumor 
clearance (at an HE4 cutoff value of 250 pMk, a sensitivity of 52% and a specificity of 93.8% were 
reached in predicting total macroscopic tumor clearance, P = 0.001; 95% confidence interval [CI], 
0.601–0.861). No significant association between HE4 expression and response to platinum-based 
chemotherapy could be detected instead. Moreover, plasma HE4 concentration was an independent 
prognostic factor for overall survival after the relapse (P < 0.001; hazard ratio, 18.77; 95% CI, 
4.68–75.25). 
DISCUSSION 
Despite the high recurrence rate of OC, surveillance strategies are not standardized yet. This leads 
to a variety of follow-up strategies, sharing CA-125 periodic evaluation. 
Recent advances in biomarkers research brought HE4 and other new markers to clinicians’ 
attention. After being tested for differential diagnosis between benign and malignant adnexal 
masses at first diagnosis, alone or in combination (eg, ROMA, Risk of Ovarian Malignancy 
Algorithm, combining CA-125 and HE4 values 15), they will be probably tested as screening 
instruments. Moreover, FDA has recently approved the use of HE4 in OC follow-up together with 
CA-125, even if few studies are available to date about its use in this setting 1,3,4,6,12–14 (Table 
1). Only 1 prospective controlled study has been published,3 and all of these studies analyzed a 
small number of women (8–73). 
Among the most interesting points from these articles, there is a possible prognostic role of HE4. A 
failure of HE4 levels to normalize at completion of primary therapy may indicate a poor 
prognosis,12 thus suggesting the need of a closer follow-up in these women. Even after the relapse, 
HE4 seems to maintain its prognostic role.14 HE4 was shown then as an earlier indicator of 
recurrence of OC with respect to CA-125, with a lead time of 5 to 8 months.6 Moreover, the 
sensibility and specificity of HE4, alone or in association with other markers (CA-125, CA-72.4), 
seem to be higher in the diagnosis of the OC relapse with respect to CA-125 alone, as shown by 
Plotti et al.3 Larger prospective, controlled, and randomized studies are needed to confirm these 
preliminary data. 
The other side of the question is whether the patient is advantaged by an earlier detection of the 
recurrent disease, in terms of overall survival, disease-free survival, and quality of life. 
Early detection and treatment of cancer in general or its recurrence are usually associated with 
better outcomes for patient, this being the rationale behind screening programs and follow-up 
strategies. 
In OC follow-up, periodical CA-125 evaluation can detect recurrence of cancer about 5 months 
before clinical signs or symptoms.16 At the same time, we have to remind that treatments of 
relapsing OC are rarely curative and have heavy adverse effects, and elevation of CA-125 is often 
cause of anxiety in patients undergoing follow-up. 
The main study that tried to clarify the role of CA-125 in OC follow-up was EORTC (European 
Organisation for Research and Treatment of Cancer) 55955 trial,16 a randomized study comparing 
early versus delayed treatment in women with relapsed OC. Five hundred twenty-nine women were 
assigned to treatment, on the basis of increased levels of CA-125: 265 to early treatment and 264 to 
delayed treatment. Patients in the early treatment group were treated within 28 days from the 
detection of an increased CA-125 value. Patients in the delayed treatment group were treated only at 
clinical or symptomatic relapse. Women assigned to early treatment started chemotherapy 4.8 
months earlier than those allocated to the delayed treatment. With a median follow-up of 56.9 
months, there was no evidence of a difference in overall survival between the 2 groups. In 
particular, the results provided no evidence of an improved overall survival or a better quality of life 
in the early treatment group. The authors’ explanation for these findings was that the lead time 
between CA-125 rise and the clinical recurrence could be too short for chemotherapy to give a 
beneficial effect. In this setting, HE4 employment could be a valid strategy to anticipate the 
diagnosis of the relapse as much as to get a beneficial effect from second-line chemotherapy. 
Moreover, earlier detection of the relapse could potentially lead to more patients being diagnosed 
with completely resectable recurrent disease and thus potentially to a longer survival. However, the 
efficacy in terms of survival of early surgical treatment of OC relapse has yet to be demonstrated. In 
a retrospective study on 74 patients who underwent secondary cytoreductive surgery for recurrent 
OC, Fleming et al 17 found that patients who achieved an optimal secondary cytoreduction were 
those who underwent surgical treatment of the relapse after a shorter interval time from CA-125 
elevation, in comparison to patients achieving suboptimal secondary cytoreduction (5.3 vs 16.4 
weeks; hazard ratio, 1.03; 95% CI, 1.01–1.06; P = 0.04). In other words, each week delay after CA-
125 elevation correlated with a 3% increased chance of suboptimal resection at secondary 
cytoreductive surgery. Interestingly, whereas in EORTC 55955 trial CA-125 elevation was defined 
as elevation to twice the upper limit of standard CA-125 value (>=75 U/mL), Fleming et al 17 
defined CA-125 elevation as twice the nadir value, based on the study by Santillan et al,18 which 
demonstrated that CA-125 elevations, even within the reference range, could predict disease 
recurrence with an even better lead time. However, published randomized controlled trials 
demonstrating a survival advantage with secondary cytoreductive surgery are still lacking (the 
DESKTOP 3 study is still ongoing). 
Rustin and colleagues’16 trial was criticized by Morris and Monk 19 because the interpretation of 
its results did not consider the problem of platinum sensitivity: platinum-free interval was 
imbalanced because some patients started an early treatment, and others were delayed. Furthermore, 
contemporary therapies such as bevacizumab and pegylated liposomal doxorubicin plus carboplatin 
were not available to most of the trial participants. 
A recent Cochrane Review 20 analyzed the effectiveness and safety of optimal secondary 
cytoreduction for women with platinum-sensitive recurrent epithelial OC, in 9 nonrandomized 
studies. Meta-analyses and single-study analyses showed a statistically significant prognostic 
difference between women treated with complete secondary cytoreduction and those with residual 
disease. Despite the absence of adequate randomized controlled trials, the authors conclude that in 
women with platinum-sensitive recurrent OC, the ability to achieve a complete secondary 
cytoreduction seems to be associated with significant improvement in overall survival. However, it 
is not clear whether this is solely due to surgical effect or due to tumor biology. In the absence of 
high-level evidence, the authors underline that the risks of major surgery have to be carefully 
balanced against potential benefits on a case-by-case basis. 
 
In summary, in the first published articles, HE4 has demonstrated a potential role in terms of 
diagnostic accuracy and lead time in the follow-up of OC. However, the utility of an early diagnosis 
of the OC relapse is still an open question, because at present evidence of survival advantages from 
earlier chemotherapeutic treatment is still lacking, and evidence of survival advantage from earlier 
secondary cytoreduction is still weak. Moreover, elevation of markers in the follow-up often has 
detrimental effects on patients’ quality of life, because of the charge of anxiety that it brings. An 
answer to our questions may come from ongoing studies on surgical management of recurrent OC, 
from future studies analyzing quality of life of OC patients during their follow-up and from future 
randomized trials about HE4 and follow-up. 
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